Indiana University

About: Indiana University is a education organization based out in Bloomington, Indiana, United States. It is known for research contribution in the topics: Population & Poison control. The organization has 64480 authors who have published 150058 publications receiving 6392902 citations. The organization is also known as: Indiana University system & indiana.edu.

Quadriceps Weakness and Osteoarthritis of the Knee

Abstract: Background: The quadriceps weakness commonly associated with osteoarthritis of the knee is widely believed to result from disuse atrophy secondary to pain in the involved joint. However, quadriceps...

A refined index of model performance

Abstract: In this paper, we develop, present and evaluate a refined, statistical index of model performance. This ‘new’ measure (dr) is a reformulation of Willmott's index of agreement, which was developed in the 1980s. It (dr) is dimensionless, bounded by − 1.0 and 1.0 and, in general, more rationally related to model accuracy than are other existing indices. It also is quite flexible, making it applicable to a wide range of model-performance problems. The two main published versions of Willmott's index as well as four other comparable dimensionless indices—proposed by Nash and Sutcliffe in 1970, Watterson in 1996, Legates and McCabe in 1999 and Mielke and Berry in 2001—are compared with the new index. Of the six, Legates and McCabe's measure is most similar to dr. Repeated calculations of all six indices, from intensive random resamplings of predicted and observed spaces, are used to show the covariation and differences between the various indices, as well as their relative efficacies. Copyright © 2011 Royal Meteorological Society

Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II Trial

Abstract: Purpose Nivolumab is a fully human immunoglobulin G4 programmed death–1 immune checkpoint inhibitor antibody that restores T-cell immune activity. This phase II trial assessed the antitumor activity, dose-response relationship, and safety of nivolumab in patients with metastatic renal cell carcinoma (mRCC). Patients and Methods Patients with clear-cell mRCC previously treated with agents targeting the vascular endothelial growth factor pathway were randomly assigned (blinded ratio of 1:1:1) to nivolumab 0.3, 2, or 10 mg/kg intravenously once every 3 weeks. The primary objective was to evaluate the dose-response relationship as measured by progression-free survival (PFS); secondary end points included objective response rate (ORR), overall survival (OS), and safety. Results A total of 168 patients were randomly assigned to the nivolumab 0.3- (n = 60), 2- (n = 54), and 10-mg/kg (n = 54) cohorts. One hundred eighteen patients (70%) had received more than one prior systemic regimen. Median PFS was 2.7, 4.0, a...